Multiple system atrophy

Handbook of Clinical Neurology

Volumn 84, Issue , 2007, Pages 307-

  Pfeiffer, Ronald F ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649376341     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)84046-2     Document Type: Chapter

References (198)

1. Abele M., Schulz J.B., Burk K., et al. Nerve conduction studies in multiple system atrophy. Eur Neurol 43 (2000) 221-223
2. Abele M., Schulz J.B., Burk K., et al. Evoked potentials in multiple system atrophy (MSA). Acta Neurol Scand 101 (2000) 111-115
3. Adams R.D., and Salam-Adams M. Striatonigral degeneration. In: Vinken P.J., Bruyn G.W., and Klawans H.L. (Eds). Extrapyramidal Disorders. Handbook of Clinical Neurology Vol. 5 (1986), Elsevier, Amsterdam 205-212 (49)
4. Adams R.D., van Bogaert L., and van der Eecken H. Dégénérescence nigro-striées et cérébello-nigro-striée. Psychiatry Neurol 142 (1961) 219-259 (Article in French)
5. Arndt M. Zur Pathologie des Kleinhirns. Arch Psychiatr Nervenkr 26 (1894) 404-429 (Article in German)
6. Askmark H., Eeg-Olofsson K.E., Johansson A., et al. Parkinsonism and neck extensor myopathy. A new syndrome or coincidental findings? Arch Neurol 58 (2001) 232-237
7. Bandmann O., Sweeney M.G., Daniel S.E., et al. Multiple-system atrophy is genetically distinct from identified inherited causes of spinocerebellar degeneration. Neurology 49 (1997) 1598-1604
8. Banh H.L., MacLean C., Topp T., et al. The use of tegaserod in critically ill patients with impaired gastric motility. Clin Pharmacol Ther 77 (2005) 583-586
9. Bannister R., Gibson W., Michaels L., et al. Laryngeal abductor paralysis in multiple system atrophy. A report on three necropsied cases, with observations on the laryngeal muscles and the nuclei ambigui. Brain 104 (1981) 351-368
10. Beck R.O., Betts C.D., and Fowler C.J. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 151 (1994) 1336-1341
11. Behnke S., Berg D., Naumann M., et al. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry 76 (2005) 423-425
12. Benarroch E.E., Smithson I.L., Low P.A., et al. Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure. Ann Neurol 43 (1998) 156-163
13. Benecke R. Clinical features and laboratory findings for differentiating parkinsonian syndromes. J Neurol 249 Suppl 3 (2002) III/6-III14
14. Benrud-Larson L.M., Sandroni P., Schrag A., et al. Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord 20 (2005) 951-957
15. Ben-Shlomo Y., Wenning G.K., Tison F., et al. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 48 (1997) 384-393
16. Berciano J., and Wenning G.K. The Lewis family revisited: no evidence for autosomal dominant multiple system atrophy. Parkinsonism Relat Disord 11 (2005) 363-365
17. Boesch S.M., Wenning G.K., Ransmayr G., et al. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 72 (2002) 300-303
18. Boeve B.F., Silber M.H., Ferman T.J., et al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 16 (2001) 622-630
19. Bonnet A.M., Pichon J., Vidailhet M., et al. Urinary disturbances in striatonigral degeneration and Parkinson's disease: clinical and urodynamic aspects. Mov Disord 12 (1997) 509-513
20. Bower J.H. Multiple system atrophy. In: Adler C.H., and Ahlskog J.E. (Eds). Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician (2000), Humana Press, Totowa, NJ 235-242
21. Bower J.H., Maraganore D.M., McDonnell S.K., et al. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976-1990. Neurology 49 (1997) 1284-1288
22. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 11 (2001) 351-355
23. Burn D.J., and Jaros E. Multiple system atrophy: cellular and molecular pathology. Mol Pathol 54 (2001) 419-426
24. Cairns N.J., Atkinson P.F., Kovacs T., et al. Apolipoprotein E e4 allele frequency in patients with multiple system atrophy. Neurosci Lett 221 (1997) 161-164
25. Chiò A., Magnani C., and Schiffer D. Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 13 (1998) 400-405
26. Christine C.W., and Aminoff M.J. Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance. Am J Med 117 (2004) 412-419
27. Chrysostome V., Tison F., Yekhlef F., et al. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology 23 (2004) 201-208
28. Cohen J., Low P., Fealey R., et al. Somatic and autonomic function in progressive autonomic failure and multiple system atrophy. Ann Neurol 22 (1987) 692-699
29. Colosimo C., and Pezzella F.R. The symptomatic treatment of multiple system atrophy. Eur J Neurol 9 (2002) 195-199
30. Colosimo C., Albanese A., Hughes A.J., et al. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol 52 (1995) 294-298
31. Colosimo C., Inghilleri M., and Chaudhuri K.R. Parkinson's disease misdiagnosed as multiple system atrophy by sphincter electro-myography. J Neurol 247 (2000) 559-561
32. Colosimo C., Geser F., and Wenning G.K. Clinical spectrum and pathological features of multiple system atrophy. In: LeDoux M. (Ed). Animal Models of Movement Disorders (2005), Elsevier, Amsterdam 541-570
33. Colosimo C., Tiple D., and Wenning G.K. Management of multiple system atrophy: state of the art. J Neural Transm 112 (2005) 1695-1704
34. Combarros O., Infante J., Llorca J., et al. Interleukin-1A (-889) genetic polymorphism increases the risk of multiple system atrophy. Mov Disord 18 (2003) 1385-1386
35. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy 1996. J Neurol Sci 144 (1996) 218-219
36. Dasgupta P., and Haslam C. Treatment of neurogenic bladder dysfunction. In: Fowler C.J. (Ed). Neurology of Bladder, Bowel, and Sexual Dysfunction (1999), Butterworth Heinemann, Boston 163-183
37. Degen L., Matzinger D., Merz M., et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 15 (2001) 1745-1751
38. Dejerine J., and Thomas A.A. L'atrophie olivo-ponto-cérébelleuse. Nouvelle Iconographie de la Salpêtriére 13 (1900) 330-370 (Article in French)
39. Dickson D.W., Liu W., Hardy J., et al. Widespread alterations of α-synuclein in multiple system atrophy. Am J Pathol 155 (1999) 1241-1251
40. Dickson D.W., Lin W., Liu W.K., et al. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol 9 (1999) 721-732
41. Dujardin K., Defebvre L., Krystkowiak P., et al. Executive function differences in multiple system atrophy and Parkinson's disease. Parkinsonism Relat Disord 9 (2003) 205-211
42. Eckert T., Barnes A., Dhawan V., et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 26 (2005) 912-921
43. Edwards L.L., Quigley E.M., Harned R.K., et al. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 33 (1993) 490-493
44. Eichhorn T.E., and Oertel W.H. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 16 (2001) 1176-1177
45. Fetoni V., Soliveri P., Monza D., et al. Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 66 (1999) 541-544
46. Fowler C.J. Neurological disorders of micturition and their treatment. Brain 122 (1999) 1213-1231
47. Frumkin H. Multiple system atrophy following chronic carbon disulfide exposure. Environ Health Perspect 106 (1998) 611-613
48. Gai W.P., Power J.H., Blumbergs P.C., et al. Multiple system atrophy: a new alpha-synuclein disease?. Lancet 352 (1998) 547-548
49. Gai W.P., Power J.H., Blumbergs P.C., et al. Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J Neurochem 73 (1999) 2093-2100
50. Gai W.P., Pountney D.L., Power J.H., et al. alpha-Synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. Exp Neurol 181 (2003) 68-78
51. Geser F., and Wenning G.K. Multiple system atrophy. In: Litvan I. (Ed). Atypical Parkinsonian Disorders (2005), Humana Press, Totowa, NJ 335-360
52. Ghorayeb I., Yekhlef F., Chrysostome V., et al. Sleep disorders and their determinants in multiple system atrophy. J Neurol Neurosurg Psychiatry 72 (2002) 798-800
53. Gilman S. Multiple system atrophy. In: Jankovic J.J., and Tolosa E. (Eds). Parkinson's Disease and Movement Disorders (2002), Lippincott Williams & Wilkins, Philadelphia 170-184
54. Gilman S., Low P., Quinn N., et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 8 (1998) 359-362
55. Gilman S., Low P.A., Quinn N., et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163 (1999) 94-98
56. Gilman S., May S.J., Shults C.W., et al. The North American Multiple System Atrophy Study Group. J Neural Transm 112 (2005) 1687-1694
57. Goldstein D.S. Cardiovascular autonomic dysfunction. In: Pfeiffer R.F., and Bodis-Wollner I. (Eds). Parkinson's Disease and Nonmotor Dysfunction (2005), Humana Press, Totowa, NJ 149-157
58. Goldstein D.S., Robertson D., Esler M., et al. Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med 137 (2002) 753-763
59. Goldstein D.S., Pechnik S., Holmes C., et al. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 42 (2003) 136-142
60. Gouider-Khouja N., Vidailhet M., Bonner A., et al. 'Pure' striatonigral degeneration and Parkinson's disease: a comparative clinical study. Mov Disord 10 (1995) 288-294
61. Graham J.G., and Oppenheimer D.R. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 32 (1969) 28-34
62. Hahn K., and Ebersbach G. Sonographic assessment of urinary retention in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord 20 (2005) 1499-1502
63. Hanna P.A., Jankovic J., and Kirkpatrick J.B. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol 56 (1999) 90-94
64. Hatzichristou D.G. Treatment of sexual dysfunction and infertility in patients with neurologic diseases. In: Fowler C.J. (Ed). Neurology of Bladder, Bowel, and Sexual Dysfunction (1999), Butterworth Heinemann, Boston 209-225
65. Healy D.G., Abou-Sleiman P.M., Quinn N., et al. European MSA Study Group. UCHL-1 gene in multiple system atrophy: a haplotype tagging approach. Mov Disord 20 10 (2005) 1338-1343
66. Higo R., Tayama N., Watanabe T., et al. Videofluoroscopic and manometric evaluation of swallowing function in patients with multiple system atrophy. Ann Otol Rhinol Laryngol 112 (2003) 630-636
67. Hughes A.J., Ben-Shlomo Y., Daniel S.E., et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42 (1992) 1142-1146
68. Hughes A.J., Colosimo C., Kleedorfer B., et al. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 55 (1992) 1009-1013
69. Hughes A.J., Daniel S.E., Ben-Shlomo Y., et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 (2002) 861-870
70. Hussain I.F., Brady C.M., Swinn M.J., et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71 (2001) 371-374
71. Hyson H.C., Johnson A.M., and Jog M.S. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 17 (2002) 1318-1320
72. Infante J., Llorca J., Berciano J., et al. Interleukin-8, intercellular adhesion molecule-1 and tumor necrosis factor-α gene polymorphisms and the risk for multiple system atrophy. J Neurol Sci 228 (2005) 11-13
73. Iranzo A., Santamaria J., and Tolosa E. Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Barcelona Multiple System Atrophy Study Group. Lancet 356 (2000) 1329-1330
74. Iranzo A., Santamaria J., Tolosa E., et al. Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 63 (2004) 930-932
75. Iranzo A., Santamaria J., Rye D.B., et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 65 (2005) 247-252
76. Jellinger K.A., Seppi K., and Wenning G.K. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 20 Suppl 12 (2005) S29-S36
77. Johnsen J.A., and Miller V.T. Tobacco intolerance in multiple system atrophy. Neurology 36 (1986) 986-988
78. Juh R., Pae C., Lee C., et al. Voxel based comparison of glucose metabolism in the differential diagnosis of the multiple system atrophy using statistical parametric mapping. Neurosci Res 52 (2005) 211-219
79. Kaufmann H., and Biaggioni I. Autonomic failure in neurodegenerative disorders. Semin Neurol 23 (2003) 351-363
80. Khurana R.K. Cholinergic dysfunction in Shy-Drager syndrome: effect of the parasympathomimetic agent, bethanechol. Clin Auton Res 4 (1994) 5-13
81. Kihara M., Sugenoya J., and Takahashi A. The assessment of sudomotor dysfunction in multiple system atrophy. Clin Auton Res 1 (1991) 297-302
82. Kim H.S., and Lee M.S. Frequencies of single nucleotide polymorphism in alcohol dehydrogenase7 gene in patients with multiple system atrophy and controls. Mov Disord 18 (2003) 1065-1067
83. Kim Y.T., Kwon D.D., Kim J., et al. Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int Braz J Urol 30 (2004) 275-278
84. Kimber J.R., Watson L., and Mathias C.J. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 349 (1997) 1877-1881
85. Kirchhof K., Apostolidis A.N., Mathias C.J., et al. Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: a retrospective study. Int J Impot Res 15 (2003) 293-298
86. Klein C., Brown R., Wenning G., et al. The "cold hands sign" in multiple system atrophy. Mov Disord 12 (1997) 514-518
87. Konagaya M., Konagaya Y., and Iida M. Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry 57 (1994) 1528-1531
88. Konagaya M., Sakai M., Matsuoka Y., et al. Patho-MR imaging study in the putaminal margin in multiple system atrophy. No To Shinkei 50 (1998) 383-385 (Article in Japanese)
89. Kraft E., Schwarz A., Trenkwalder C., et al. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy?. Arch Neurol 56 (1999) 225-228
90. Kumazawa K., Sobue G., Nakao N., et al. Postganglionic sudomotor function in multiple system atrophy. Rinsho Shinkeigaku 29 (1989) 1357-1363 (Article in Japanese)
91. Kurisaki H. Prognosis of multiple system atrophy-survival time with or without tracheostomy. Rinsho Shinkeigaku 39 (1999) 503-507 (Article in Japanese)
92. Lange K.W., Tucha O., Alders G.L., et al. Differentiation of parkinsonian syndromes according to differences in executive functions. J Neural Transm 110 (2003) 983-995
93. Lantos P.L., and Papp M.I. Cellular pathology of multiple system atrophy: a review. J Neurol Neurosurg Psychiatry 57 (1994) 129-133
94. Lewis P. Familial orthostatic hypotension. Brain 87 (1964) 719-728
95. Limberg N., Jeavons S., Robertson T., et al. Pyramidal tract imaging in multiple-system atrophy. Mov Disord 20 (2005) 1527-1528
96. Litvan I., Goetz C.G., Jankovic J., et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 54 (1997) 937-944
97. Low P.A., Gilden J.L., Freeman R., et al. for the Midodrine Study Group. Efficacy of midodrine vs. placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. JAMA 277 (1997) 1046-1051
98. Mabuchi N., Hirayama M., Koike Y., et al. Progression and prognosis in pure autonomic failure (PAF): comparison with multiple system atrophy. J Neurol Neurosurg Psychiatry 76 (2005) 947-952
99. Mancini F., Zangaglia R., Cristina S., et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18 (2003) 685-688
100. Mathers S.E., Kempster P.A., Law P.J., et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 46 (1989) 1061-1064
101. Mathias C.J. Autonomic diseases: management. J Neurol Neurosurg Psychiatry 74 Suppl 3 (2003) iii42-iii47
102. Mathias C.J. Cardiovascular autonomic dysfunction in Parkinson's disease and parkinsonian syndromes. In: Ebadi M., and Pfeiffer R.F. (Eds). Parkinson's Disease (2005), CRC Press, Boca Raton 295-317
103. Mathias C.J., Mallipeddi R., and Bleasdale-Barr K. Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy. J Neurol 246 (1999) 893-898
104. Matsuo A., Akiguchi I., Lee G.C., et al. Myelin degeneration in multiple system atrophy detected by unique antibodies. Am J Pathol 153 (1998) 735-744
105. Merlo I.M., Occhini A., Pacchetti C., et al. Not paralysis, but dystonia causes stridor in multiple system atrophy. Neurology 58 (2002) 649-652
106. Montorsi F. Assessment, diagnosis, and investigation of erectile dysfunction. Clin Cornerstone 7 (2005) 29-35
107. Morris H.R., Vaughan J.R., Datta S.R., et al. Multiple system atrophy/progressive supranuclear palsy: α-synuclein, synphilin, tau, and APOE. Neurology 55 (2000) 1918-1920
108. Muller J., Wenning G.K., Verny M., et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol 58 (2001) 259-264
109. Nahm F., and Freeman R. Sphincter electromyography and multiple system atrophy. Muscle Nerve 28 (2003) 18-26
110. Nee L.E., Gomez M.R., Dambrosia J., et al. Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res 1 (1991) 9-13
111. Nee L.E., Scott J., and Polinsky R.J. Olfactory dysfunction in the Shy-Drager syndrome. Clin Auton Res 3 (1993) 281-282
112. Nicholl D.J., Bennett P., Hiller L., et al., for the European Study Group on Atypical Parkinsonism. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. Neurology 53 (1999) 1415-1421
113. Oertel W.H., Wachter T., Quinn N.P., et al. Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type. Mov Disord 18 (2003) 430-432
114. Papp M.I., and Lantos P.L. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci 107 (1992) 172-182
115. Papp M.I., and Lantos P.L. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 117 (1994) 235-243
116. Papp M.I., Kahn J.E., and Lantos P.L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94 (1989) 79-100
117. Parati E.A., Fetoni V., Geminiani G.C., et al. Response to L-DOPA in multiple system atrophy. Clin Neuropharmacol 16 (1993) 139-144
118. Pathak A., Lapeyre-Mestre M., Montastruc J., et al. Heat-related morbidity in patients with orthostatic hypotension and primary autonomic failure. Mov Disord 20 (2005) 1213-1219
119. Paviour D.C., Williams D., Fowler C.J., et al. Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosis. Mov Disord 20 (2005) 1425-1430
120. Pellecchia M.T., Salvatore E., Pivonello R., et al. Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease, and idiopathic cerebellar ataxia. Neurol Sci 22 (2001) 79-80
121. Pechere-Bertschi A., Nussberger J., Biollaz J., et al. Circadian variations of renal sodium handling in patients with orthostatic hypotension. Kidney Int 54 (1998) 1276-1282
122. Pezzoli G., Canesi M., and Galli C. An overview of parkinsonian syndromes: data from the literature and from an italian data-base. Sleep Med 5 (2004) 181-187
123. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. In: Ebadi M., and Pfeiffer R.F. (Eds). Parkinson's Disease (2005), CRC Press, Boca Raton 259-273
124. Pfeiffer R.F. Intestinal dysfunction. In: Pfeiffer R.F., and Bodis-Wollner I. (Eds). Parkinson's Disease and Nonmotor Dysfunction (2005), Humana Press, Totowa, NJ 115-125
125. Pierangeli G., Provini F., Maltoni P., et al. Nocturnal body core temperature falls in Parkinson's disease but not in multiple-system atrophy. Mov Disord 16 (2001) 226-232
126. Planté-Bordeneuve V., Bandmann O., Wenning G., et al. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy. Mov Disord 10 (1995) 277-278
127. Plazzi G., Corsini R., Provini F., et al. REM sleep behavior disorders in multiple system atrophy. Neurology 48 (1997) 1094-1097
128. Polinsky R.J. Multiple system atrophy. Clinical aspects, pathophysiology, and treatment. Neurol Clin 2 (1984) 487-498
129. Pramstaller P.P., Wenning G.K., Smith S.J., et al. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 58 (1995) 618-621
130. Pountney D.L., Treweek T.M., Chataway T., et al. Alpha B-crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy. Neurotox Res 7 (2005) 77-85
131. Pountney D.L., Chegini F., Shen X., et al. SUMO-1 marks subdomains within glial cytoplasmic inclusions of multiple system atrophy. Neurosci Lett 381 (2005) 74-79
132. Quinn N. Multiple system atrophy-the nature of the beast. J Neurol Neurosurg Psychiatry 52 Suppl (1989) 78-89
133. Quinn N. Disproportionate antecollis in multiple system atrophy. Lancet 1 (1989) 844
134. Quinn N.P. How to diagnose multiple system atrophy. Mov Disord 20 Suppl 12 (2005) S5-S10
135. Racette B.A., Good L., Sagitto S., et al. Botulinum toxin B reduces sialorrhea in parkinsonism. Mov Disord 18 (2003) 1059-1061
136. Rajput A.H., Rozdilsky B., Rajput A., et al. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 13 (1990) 553-558
137. Rajput A.H., Uitti R.J., Fenton M.E., et al. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 3 (1998) 211-214
138. Riley D.E. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 72 (2002) 286
139. Rivest J., Quinn N., and Marsden C.D. Dystonia in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurology 40 (1990) 1571-1578
140. Saito Y., Matsuoka Y., Takahashi A., et al. Survival of patients with multiple system atrophy. Intern Med 33 (1994) 321-325
141. Sakakibara R., Hattori T., Tojo M., et al. Micturitional disturbance in multiple system atrophy. Jpn J Psychiatry Neurol 47 (1993) 591-598
142. Sakakibara R., Hattori T., Uchiyama T., et al. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation?. J Neurol Neurosurg Psychiatry 68 (2000) 65-69
143. Sakakibara R., Hattori T., Uchiyama T., et al. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 71 (2001) 600-606
144. Sakakibara R., Odaka T., Uchiyama T., et al. Colonic transit time, sphincter EMG, and rectoanal videomanometry in multiple system atrophy. Mov Disord 19 (2004) 924-929
145. Sakakibara R., Hiruma K., Arai K., et al. Head-turning dizziness in multiple system atrophy. Parkinsonism Relat Disord 10 (2004) 255-256
146. Salazar G., Valls-Sole J., Marti M.J., et al. Postural and action myoclonus in patients with parkinsonian type multiple system atrophy. Mov Disord 15 (2000) 77-83
147. Schatz I.J. A remarkable patient-40 years with probable multiple system atrophy (MSA). Clin Auton Res 13 (2003) 221-223
148. Schultze V. Über einen Fall von Kleinhirnschwund mit Degenerationen im verlängerten Marke und im Rückenmarke (wahrscheinlich in Folge von Alkoholismus). Virchows Arch Pathol Anat 108 (1887) 331-343 (Article in German)
149. Schrag A., Kingsley D., Phatouros C., et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 65 (1998) 65-71
150. Schrag A., Ben-Shlomo Y., and Quinn N.P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354 (1999) 1771-1775
151. Schwarz J., Weis S., Kraft E., et al. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 60 (1996) 98-101
152. Seppi K., Schocke M.F., Wenning G.K., et al. How to diagnose MSA early: round table magnetic resonance imaging. J Neural Transm 112 (2005) 1625-1634
153. Shulman L.M., Minagar A., and Weiner W.J. Multiple-system atrophy. In: Watts R.L., and Koller W.C. (Eds). Movement Disorders: Neurologic Principles and Practice. second edn. (2004), McGraw-Hill, New York 359-369
154. Shy G.M., and Drager G.A. A neurological syndrome associated with orthostatic hypotension. Arch Neurol 2 (1960) 511-527
155. Silber M.H., and Levine S. Stridor and death in multiple system atrophy. Mov Disord 15 (2000) 699-704
156. Simpson D.M., Kaufmann H., Sanders I., et al. Laryngeal dystonia in multiple system atrophy. Muscle Nerve 15 (1992) 1213-1215
157. Slawek J., Derejko M., Lass P., et al. Camptocormia or Pisa syndrome in multiple system atrophy. Clin Neurol Neurosurg 108 (2006) 699-704
158. Smith C.P., Nishiguchi J., O'Leary M., et al. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65 (2005) 37-41
159. Stocchi F., Badiali D., Vacca L., et al. Anorectal function in multiple system atrophy and Parkinson's disease. Mov Disord 15 (2000) 71-76
160. Strijks E., van't Hof M., Sweep F., et al. Stimulation of growth-hormone release with clonidine does not distinguish individual cases of idiopathic Parkinson's disease from those with striatonigral degeneration. J Neurol 249 (2002) 1206-1210
161. Tachibana N., Kimura K., Kitajima K., et al. REM sleep motor dysfunction in multiple system atrophy: with special emphasis on sleep talk as its early clinical manifestation. J Neurol Neurosurg Psychiatry 63 (1997) 678-681
162. Tarsy D., Apetauerova D., Ryan P., et al. Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy. Neurology 61 (2003) 247-249
163. Testa D., Monza D., Ferrarini M., et al. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci 22 (2001) 247-251
164. Thobois S., Broussole E., Toureille L., et al. Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy. Mov Disord 16 (2001) 764-765
165. Thomaides T., Bleasdale-Barr K., Chaudhuri K.R., et al. Cardiovascular and hormonal responses to liquid food challenge in idiopathic Parkinson's disease, multiple system atrophy, and pure autonomic failure. Neurology 43 (1993) 900-904
166. Thomaides T., Karapanayiotides T., Zoukos Y., et al. Gastric emptying after semi-solid food in multiple system atrophy and Parkinson disease. J Neurol 252 (2005) 1055-1059
167. Tison F., Wenning G.K., Quinn N.P., et al. REM sleep behaviour disorder as the presenting symptom of multiple system atrophy. J Neurol Neurosurg Psychiatry 58 (1995) 379-380
168. Tison F., Yekhlef F., Chrysostome V., et al. Prevalence of multiple system atrophy. Lancet 355 (2000) 495-496
169. Tison F., Yekhlef F., Chrysostome V., et al. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease. Mov Disord 17 (2002) 701-709
170. Tranchant C., Guiraud-Chaumeil C., Echaniz-Laguna A., et al. Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from Parkinson's disease?. J Neurol 247 (2000) 853-856
171. Trenkwalder C., Schwarz J., Gebhard J., et al. Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 52 (1995) 1017-1022
172. Uzawa A., Sakakibara R., Tamura N., et al. Laryngeal abductor paralysis can be a solitary manifestation of multiple system atrophy. J Neurol Neurosurg Psychiatry 76 12 (2005) 1739-1741
173. Valldeoriola F., Valls-Sole J., Tolosa E.S., et al. Striated anal sphincter denervation in patients with progressive supranuclear palsy. Mov Disord 10 (1995) 550-555
174. van der Eecken H., Adams R.D., and van Bogaert L. Striopallidal-nigral degeneration: a hitherto undescribed lesion in paralysis agitans. J Neuropathol Exp Neurol 19 (1960) 159-161
175. Vanacore N., Bonifati V., Fabbrini G., et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 54 (2000) 114-119
176. Vanacore N., Bonifati V., Fabbrini G., et al., for the ESGAP Consortium. Epidemiology of multiple system atrophy. Neurol Sci 22 (2001) 97-99
177. Vanacore N., Bonifati V., Fabbrini G., et al., the ESGAP Consortium. Case-control study of multiple system atrophy. Mov Disord 20 (2005) 158-163
178. Vetrugno R., Provini F., Cortelli P., et al. Sleep disorders in multiple system atrophy: a correlative video-polysomnographic study. Sleep Med 5 (2004) 21-30
179. Visser-Vandewalle V., Temel Y., Colle H., et al. Bilateral high-frequency stimulation of the subthalamic nucleus in patients with multiple system atrophy-parkinsonism. Report of four cases. J Neurosurg 98 (2003) 882-887
180. Wakabayashi K., Yoshimoto M., Tsuji S., et al. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249 (1998) 180-182
181. Walter U., Niehaus L., Probst T., et al. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 60 (2003) 74-77
182. Watanabe H., Saito Y., Terao S., et al. Progression and prognosis in multiple system atrophy. An analysis of 230 Japanese patients. Brain 125 (2002) 1070-1083
183. Wenning G.K., and on behalf of the Working Group on Atypical Parkinsonism of the Austrian Parkinson's Society. Placebo-controlled trial of amantadine in multiple system atrophy. Clin Neuropharmacol 28 (2005) 225-227
184. Wenning G.K., Ben-Shlomo Y., Magalhaes M., et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 117 (1994) 835-845
185. Wenning G.K., Ben-Shlomo Y., Magalhaes M., et al. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 58 (1995) 160-166
186. Wenning G.K., Shephard B., Hawkes C., et al. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 91 (1995) 247-250
187. Wenning G.K., Tison F., Ben Shlomo Y., et al. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12 (1997) 133-147
188. Wenning G.K., Scherfler C., Granata R., et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 67 (1999) 620-623
189. Wenning G.K., Geser F., Stampfer-Kountchev M., et al. Multiple system atrophy: an update. Mov Disord 18 Suppl 6 (2003) S34-S42
190. Wenning G.K., Geser F., and Poewe W. The "risus sardonicus" of multiple system atrophy. Mov Disord 18 (2003) 1211
191. Wenning G.K., Colosimo C., Geser F., et al. Multiple system atrophy. Lancet Neurol 3 (2004) 93-103
192. Wenning G.K., Geser F., and Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord 20 Suppl 12 (2005) S67-S76
193. Wermuth L., Joensen P., Bünger N., et al. High prevalence of Parkinson's disease in the Faroe Islands. Neurology 49 (1997) 426-432
194. Wetter T.C., Collado-Seidel V., Pollmacher T., et al. Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep 23 (2000) 361-367
195. Winkler A.S., Landau S., Watkins P., et al. Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure. Clin Auton Res 12 (2002) 203-206
196. Wu Y.R., Chen C.M., Ro L.S., et al. Sensory neuropathy as the initial manifestation of multiple system atrophy. J Formos Med Assoc 103 (2004) 727-730
197. Wüllner U., Abele M., Schmitz-Huebsch T., et al. Probable multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 75 (2004) 924-925
198. Yamaguchi M., Arai K., Asahina M., et al. Laryngeal stridor in multiple system atrophy. Eur Neurol 49 (2003) 154-159